Grifols, S.A. Q3 2025 Earnings Recap

Grifols delivered solid third-quarter performance with 7.7% revenue growth year-over-year, reflecting strong demand and effective cost management while facing external pressures.

Key Takeaways

• Year-to-date revenue reached EUR 5.5 billion, with a 10.5% increase on a like-for-like basis at constant currency.
• Adjusted EBITDA for the third quarter was EUR 482 million, contributing to a total of EUR 1,358 million year-to-date, up 11.2% year-over-year.
• Free cash flow improved significantly to EUR 188 million, marking a EUR 257 million increase versus the previous year.
• Leverage ratio improved nearly 1x year-over-year to 4.2x, reflecting the company’s commitment to deleveraging.
• Grifols remains on track to launch its fibrinogen therapy in Europe by late 2025 and is advancing strong clinical pipelines despite regulatory complexities.